Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 10/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12406987 | 0.84 | KEAP1 (0.46) | MEN1LMNAKMT2APTGER1OXTR | |
| SCHEMBL2176077 | 0.78 | KEAP1 (0.64) | MEN1LMNAKMT2APTGER1OXTR | |
| SCHEMBL12406996 | 0.77 | MEN1 (0.57) | MEN1LMNAKMT2APTGER1OXTR | |
| SCHEMBL2177715 | 0.77 | PTGER1 (0.44) | MEN1LMNAKMT2APTGER1OXTR | |
| SCHEMBL12481950 | 0.75 | ESR1 (0.62) | MEN1LMNAKMT2APTGER1PSEN1 | |
| SCHEMBL12407191 | 0.75 | HPGD (0.57) | MEN1LMNAKMT2APTGER1OXTR | |
| SCHEMBL12407000 | 0.74 | MEN1 (0.54) | MEN1LMNAKMT2APTGER1OXTR | |
| SCHEMBL2176662 | 0.74 | PTGER1 (0.52) | MEN1LMNAKMT2APTGER1OXTR | |
| SCHEMBL12407448 | 0.73 | PTGER1 (0.52) | PTGER1OXTR | |
| SCHEMBL17481680 | 0.73 | AGER (0.54) | MEN1KMT2AKEAP1NFE2L2C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2050446-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | MEN1 3347/4885LMNA 4123/4885KMT2A 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.